Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
June 2012, Vol 3, No 4
June 2012, Vol 3, No 4
Patients with Cancer Willing to Pay More for Unproven, but Promising, Therapies
In the Literature
June 2012, Vol 3, No 4
Assessments of the value of cancer therapies have been based on the assumption that stakeholders care most about average or median gain in survival or quality-adjusted survival.
Read Article
Will Merger of 2 Major Diagnostic Centers Up Access to Molecular Imaging?
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
Two of the largest diagnostic imaging centers in the country—Insight Imaging in California and Centers for Diagnostic Imaging (CDI) in Minneapolis—have announced that they are merging forces.
Read Article
Radium-223 Offers New Hope for Patients with Bone Metastases
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
At the 2012 annual meeting of the Society of Nuclear Medicine, researchers presented new results for the radioisotope therapy radium-223 chloride, suggesting that these results represent a new treatment protocol for patients with advanced prostate cancer that has spread to the bone.
Read Article
Understanding Genes Is Crucial to Predicting Response to Breast Cancer Therapy
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
A study funded by the National Cancer Institute, the National Institutes of Health, a Theodore N. Law Endowment for Scientific Achievement, and a Dodie P. Hawn Fellowship in Cancer Genetics Research surprisingly showed that the presence of normal
p53
, a tumor suppressor gene and not the mutated gene, was making chemotherapy with doxorubicin less effective in breast cancer; it is the mutated gene that actually enhances the benefit of the drug and not the reverse.
Read Article
In a Policy Reversal, FDA Concedes Value of Accelerating Approval of Early-Stage Breast Cancer Drugs
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
The FDA has reversed its long-standing policy regarding breast cancer trials that could greatly reduce the time and cost of new drug development for early-stage breast cancer.
Read Article
Personalized Medicine the “Crown Jewel” of Drug Development
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
The recent trend in drug development of shifting away from one-size-fits-all cancer medications to targeted therapies, which is the key to personalized medicine, points to the value of and monetary benefits of developing drugs that target the molecular levels of cancer cells.
Read Article
Safety Warnings Added to Lenalidomide
FDA Approvals, News & Updates
June 2012, Vol 3, No 4
The FDA has added new safety information to the label and medication guide for lenalidomide (Revlimid; Celgene), noting that lenalidomide maintenance treatment in patients with newly diagnosed multiple myeloma is associated with an increased risk for developing new primary malignancies.
Read Article
FDA Expedites Approval of Pertuzumab for Metastatic HER2 Breast Cancer
FDA Approvals, News & Updates
June 2012, Vol 3, No 4
The US Food and Drug Administration (FDA) approved pertuzumab (Perjeta; Genentech) for intravenous use in patients with HER2-positive metastatic breast cancer.
Read Article
Can Pathways Improve Quality of Care While Reducing Cost?
By
Neil Canavan
ACCC Annual Meeting
June 2012, Vol 3, No 4
Baltimore, MD—Changes are constant in cancer care—new technologies, new targets, and new treatments. But the associated spiraling costs are also constant.
Read Article
Regional Cancer Care Associates: Consolidating Small Practices into a Large Consortium
Best Practices
,
Policies & Guidelines
June 2012, Vol 3, No 4
Value-Based Cancer Care
is focused on examining value within the context of healthcare stakeholder relations. Dr Pecora and his team at Regional Cancer Care Associates (RCCA) have changed the relationship between the practicing oncologist and the payer, which will have substantial effects on value.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma